All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Anti-CD19 h(28ζ) CART, Combined with Tws119 represents a CAR Plus system, which can be used in the research of B cell malignancies. In the system, the transduced CAR lentiviral vector was constructed to express scFv of an anti-CD19 antibody linked to the CD28-CD3ζ signaling domains.The CAR Plus system combined Tws119 to improve the antitumor activity and reduce CRS in adoptive immunotherapy. Creative Biolabs provides customized CAR Plus system design and construction services. Please contact us for more detailed information.
There are currently no customer reviews or questions for Anti-CD19 h(28ζ) CART, Combined with Tws119, a CAR Plus System (CARP-LX-018). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION